Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:12:23.360Z.
Calculation as of: 2026-10-06T14:12:23.360Z.
Quote observation: 2026-10-06T14:09:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d0a5a873814bcf3bdb8f0629e8f85f3c34e344d7cd5b6e560bd2cf85b63415c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Intelligent Bio Solutions Inc.
Market Cap
$5.57M
EV/EBIT Ratio
N/A
Market Cap
$5.82M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.57M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.33M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.36M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.40M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.21M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.94M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.04M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.14M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
